COV — CLEO Diagnostics Cashflow Statement
0.000.00%
- AU$48.19m
- AU$41.73m
- AU$1.18m
Annual cashflow statement for CLEO Diagnostics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final |
Changes in Working Capital | — | — | 0.56 | 1.15 |
Other Operating Cash Flow | ||||
Cash from Operating Activities | 0 | -0.684 | -2.03 | -2.9 |
Capital Expenditures | -0.2 | -0.34 | -0.003 | -0.011 |
Purchase of Fixed Assets | ||||
Purchase / Acquisition of Intangibles | ||||
Cash from Investing Activities | -0.2 | -0.34 | -0.003 | -0.011 |
Financing Cash Flow Items | — | -0.182 | -0.834 | 0 |
Other Financing Cash Flow | ||||
Net Issuance / Retirement of Stock | ||||
Net Issuance / Retirement of Debt | ||||
Cash from Financing Activities | 0.243 | 1.22 | 11.2 | 0 |
Beginning Cash Balance | ||||
Ending Cash Balance | ||||
Net Change in Cash | 0.043 | 0.197 | 9.13 | -2.91 |